Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)

NANot yet recruitingINTERVENTIONAL

Enrollment

280

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Spontaneous Bacterial Peritonitis

Interventions

DRUG

Rifaximin

Rifaximin 550 mg BD

DRUG

Norfloxacin

Norfloxacin 400 mg OD

Trial Locations (1)

Dr Jaya Benjamin, New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06199843 - Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial) | Biotech Hunter | Biotech Hunter